Collectively, these results clearly demonstrated that metformin and LKB1 inhibited the effect of TGF-β on phosphorylation of Smad2/3, leading to suppression of its transcription activity in breast cancer cells and in precancerous lesion. This evidence concerns the gene SMAD2 and breast cancer.